应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
PTCT PTC Therapeutics Inc.
交易中 12-19 09:40:28 EST
75.61
+1.02
+1.36%
最高
75.61
最低
74.57
成交量
8.08万
今开
75.29
昨收
74.59
日振幅
1.39%
总市值
60.70亿
流通市值
49.15亿
总股本
8,029万
成交额
608.49万
换手率
0.12%
流通股本
6,501万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
PTC Therapeutics 宣布加拿大卫生部批准 Sephience™ (Sepiapterin) 用于治疗患有苯丙酮尿症 (PKU) 的儿童和成人
美股速递 · 12-10
PTC Therapeutics 宣布加拿大卫生部批准 Sephience™ (Sepiapterin) 用于治疗患有苯丙酮尿症 (PKU) 的儿童和成人
指数成分股调整公告：SanDisk取代埃培智成为标普500指数成分股
老虎资讯综合 · 11-25
指数成分股调整公告：SanDisk取代埃培智成为标普500指数成分股
异动解读 | PTC Therapeutics股价盘中大涨5.92%，多家券商上调目标价
异动解读 · 11-05
异动解读 | PTC Therapeutics股价盘中大涨5.92%，多家券商上调目标价
异动解读 | 多家券商上调目标价，PTC Therapeutics盘前大涨5.58%
异动解读 · 11-05
异动解读 | 多家券商上调目标价，PTC Therapeutics盘前大涨5.58%
异动解读 | PTC Therapeutics股价盘中大跌6.91%，季度业绩远低于预期
异动解读 · 08-08
异动解读 | PTC Therapeutics股价盘中大跌6.91%，季度业绩远低于预期
PTC Therapeutics盘前涨超10%
格隆汇 · 07-29
PTC Therapeutics盘前涨超10%
基因疗法药物研发商PTC Therapeutics宣布Sephience™获得欧盟委员会批准，治疗患有苯丙酮尿症（PKU）的儿童和成人Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
动脉网 · 06-25
基因疗法药物研发商PTC Therapeutics宣布Sephience™获得欧盟委员会批准，治疗患有苯丙酮尿症（PKU）的儿童和成人Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics(PTCT.US)获Scotiabank首次覆盖，给予与大盘持平评级, 目标价55.00美元。
金融界 · 03-08
PTC Therapeutics(PTCT.US)获Scotiabank首次覆盖，给予与大盘持平评级, 目标价55.00美元。
Ptc Therapeutics, Inc.2024财年实现净利润-3.63亿美元，同比增加42.11%
市场透视 · 03-08
Ptc Therapeutics, Inc.2024财年实现净利润-3.63亿美元，同比增加42.11%
Ptc Therapeutics, Inc.盘中异动 股价大跌5.52%
市场透视 · 03-04
Ptc Therapeutics, Inc.盘中异动 股价大跌5.52%
小摩：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至72.00美元。
金融界 · 03-01
小摩：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至72.00美元。
PTC Therapeutics 2024年第四季度调整后每股收益$(0.85) 低于预期$(0.66)，销售额$2.13亿 低于预期$2.3244亿
财报速递 · 02-28
PTC Therapeutics 2024年第四季度调整后每股收益$(0.85) 低于预期$(0.66)，销售额$2.13亿 低于预期$2.3244亿
加拿大皇家银行：维持PTC Therapeutics(PTCT.US)评级，由优于大市调整至优于大市评级, 目标价由60.00美元调整至63.00美元。
金融界 · 02-19
加拿大皇家银行：维持PTC Therapeutics(PTCT.US)评级，由优于大市调整至优于大市评级, 目标价由60.00美元调整至63.00美元。
坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由76.00美元调整至113.00美元。
金融界 · 02-04
坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由76.00美元调整至113.00美元。
Ptc Therapeutics, Inc.盘中异动 快速上涨5.11%
市场透视 · 02-03
Ptc Therapeutics, Inc.盘中异动 快速上涨5.11%
坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由80.00美元调整至76.00美元。
金融界 · 01-15
坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由80.00美元调整至76.00美元。
Ptc Therapeutics, Inc.盘中异动 快速拉升6.08%报50.98美元
市场透视 · 2024-12-10
Ptc Therapeutics, Inc.盘中异动 快速拉升6.08%报50.98美元
Ptc Therapeutics, Inc.盘中异动 下午盘股价大跌5.17%报49.38美元
市场透视 · 2024-12-04
Ptc Therapeutics, Inc.盘中异动 下午盘股价大跌5.17%报49.38美元
Ptc Therapeutics, Inc.股价飙升15.43% 市值涨6.03亿美元
市场透视 · 2024-12-02
Ptc Therapeutics, Inc.股价飙升15.43% 市值涨6.03亿美元
PTC Therapeutics(PTCT.US)与诺华制药(NVS.US)签署亨廷顿病药物许可协议
智通财经 · 2024-12-02
PTC Therapeutics(PTCT.US)与诺华制药(NVS.US)签署亨廷顿病药物许可协议
加载更多
公司概况
公司名称：
PTC Therapeutics Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Ptc Therapeutics, Inc.于1998年3月31日注册成立为一家特拉华州公司。 PTC Therapeutics股份有限公司是一家生物制药公司，专注于用于转录后控制过程中的口服药，专有的小分子药物的发现和开发。同时该公司的研发计划针对于多个治疗领域，公司特别专注于孤儿和超孤儿混乱疾病的治疗的开发和商业化。公司主导的候选产品是ataluren，该产品用于治疗过程中所出现的一种被称为无义突变基因突变的遗传性疾病的治疗。
发行价格：
--
{"stockData":{"symbol":"PTCT","market":"US","secType":"STK","nameCN":"PTC Therapeutics Inc.","latestPrice":75.605,"timestamp":1766155202423,"preClose":74.59,"halted":0,"volume":80821,"delay":0,"floatShares":65010181,"shares":80288305,"eps":8.939479,"marketStatus":"交易中","change":1.015,"latestTime":"12-19 09:40:28 EST","open":75.29,"high":75.605,"low":74.57,"amount":6084879.73535,"amplitude":0.013876,"askPrice":76,"askSize":118,"bidPrice":75.21,"bidSize":114,"shortable":3,"etf":0,"ttmEps":8.939479,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1766178000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1371700800000,"exchange":"NASDAQ","adjPreClose":74.59,"preHourTrading":{"tag":"盘前","latestPrice":74.8,"preClose":74.59,"latestTime":"08:21 EST","volume":155,"amount":11593.2312,"timestamp":1766150505026},"postHourTrading":{"tag":"盘后","latestPrice":74.59,"preClose":74.59,"latestTime":"19:36 EST","volume":194642,"amount":14518371.14,"timestamp":1766104602823},"volumeRatio":2.340712,"impliedVol":0.5194,"impliedVolPercentile":0.496},"requestUrl":"/m/hq/s/PTCT","defaultTab":"news","newsList":[{"id":"1154048337","title":"PTC Therapeutics 宣布加拿大卫生部批准 Sephience™ (Sepiapterin) 用于治疗患有苯丙酮尿症 (PKU) 的儿童和成人","url":"https://stock-news.laohu8.com/highlight/detail?id=1154048337","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154048337?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:07","pubTimestamp":1765372052,"startTime":"0","endTime":"0","summary":"PTC Therapeutics 宣布加拿大卫生部批准 Sephience™ (Sepiapterin) 用于治疗患有苯丙酮尿症 (PKU) 的儿童和成人","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0109394709.USD","PTCT","BK4139","LU0889565916.HKD"],"gpt_icon":0},{"id":"1162593542","title":"指数成分股调整公告：SanDisk取代埃培智成为标普500指数成分股","url":"https://stock-news.laohu8.com/highlight/detail?id=1162593542","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162593542?lang=zh_cn&edition=full","pubTime":"2025-11-25 07:06","pubTimestamp":1764025560,"startTime":"0","endTime":"0","summary":"美东时间11月24日盘后，标普道琼斯指数官网发布公告，对标普 500 指数、标普小盘股 600 指数作出如下调整：$SanDisk Corp$将取代$埃培智$纳入标普 500 指数，$PTC Therapeutics$ 将取代SanDisk纳入标普小盘股 600 指数，上述调整将于 11 月 28 日（周五）开盘前生效。Patient Square 资本正在收购 $Premier $公司，该交易有待最终交割条件满足，预计于 11 月 25 日完成。消息公布后，Sandisk股价盘后涨近8%，PTC Therapeutics股价盘后涨超5%。","market":"us","thumbnail":"https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d695c9056389e84bfc97abfcaa826436","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"指数成分股调整公告：SanDisk取代埃培智成为标普500指数成分股","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDK","PTCT"],"gpt_icon":1},{"id":"1148863553","title":"异动解读 | PTC Therapeutics股价盘中大涨5.92%，多家券商上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1148863553","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148863553?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:41","pubTimestamp":1762353704,"startTime":"0","endTime":"0","summary":"周三盘中，生物制药公司PTC Therapeutics股价大涨5.92%，投资者对该公司前景的乐观情绪明显升温。推动股价上涨的主要因素是多家知名券商纷纷上调了PTC Therapeutics的目标价。这些目标价的上调可能反映了分析师对PTC Therapeutics在罕见病治疗领域的研发进展和市场潜力的看好。虽然具体上调原因尚未公开，但投资者显然对这些积极的分析师评级做出了正面反应。市场将密切关注PTC Therapeutics股价的后续表现，以及公司是否会发布任何重要公告来支撑这波涨势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PTCT"],"gpt_icon":0},{"id":"1142300580","title":"异动解读 | 多家券商上调目标价，PTC Therapeutics盘前大涨5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142300580","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142300580?lang=zh_cn&edition=full","pubTime":"2025-11-05 17:48","pubTimestamp":1762336130,"startTime":"0","endTime":"0","summary":"周三盘前，生物制药公司PTC Therapeutics股价大涨5.58%，投资者对该公司前景的乐观情绪明显升温。推动股价上涨的主要因素是多家知名券商纷纷上调了PTC Therapeutics的目标价。这些目标价的上调可能反映了分析师对PTC Therapeutics在罕见病治疗领域的研发进展和市场潜力的看好。虽然具体上调原因尚未公开，但投资者显然对这些积极的分析师评级做出了正面反应。随着市场开盘，投资者将密切关注PTC Therapeutics股价的后续表现，以及公司是否会发布任何重要公告来支撑这波涨势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PTCT"],"gpt_icon":0},{"id":"1174206347","title":"异动解读 | PTC Therapeutics股价盘中大跌6.91%，季度业绩远低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1174206347","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174206347?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:38","pubTimestamp":1754660326,"startTime":"0","endTime":"0","summary":"周五盘中，PTC Therapeutics Inc.股价大跌6.91%，主要原因是该公司公布的季度业绩远低于市场预期。根据公司最新发布的财报，截至6月30日的季度，PTC Therapeutics调整后每股亏损83美分，远高于分析师平均预期的21美分亏损。值得注意的是，尽管公司本季度每股收益为10.04美元，但当季仍亏损6485万美元。这一业绩表现显著低于市场预期，导致投资者信心受挫。尽管如此，华尔街分析师对PTC Therapeutics的12个月目标价中位数仍为64.00美元，较当前股价有约21.3%的上涨空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PTCT"],"gpt_icon":0},{"id":"2555503283","title":"PTC Therapeutics盘前涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555503283","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555503283?lang=zh_cn&edition=full","pubTime":"2025-07-29 17:45","pubTimestamp":1753782349,"startTime":"0","endTime":"0","summary":"格隆汇7月29日｜生物制药公司PTC Therapeutics的代谢疾病治疗药物获FDA批准，股价盘前涨超10%。巴克莱银行上调其目标价至46美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072917482497252381&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072917482497252381&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU1951200564.SGD","PTC","LU2477742899.HKD","BK4023","LU2506952337.HKD","PTCT","LU2362541513.USD","LU1951198990.SGD","BK4588","BK4554","BK4139","LU1923623000.USD","BK4576","LU2362541273.HKD","BK4585","BK4539","BK4007","LENZ","LU2362540622.SGD","LU0109394709.USD","LU1721428347.USD","LU2506952410.USD"],"gpt_icon":0},{"id":"2546126867","title":"基因疗法药物研发商PTC Therapeutics宣布Sephience™获得欧盟委员会批准，治疗患有苯丙酮尿症（PKU）的儿童和成人Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546126867","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546126867?lang=zh_cn&edition=full","pubTime":"2025-06-25 09:50","pubTimestamp":1750816200,"startTime":"0","endTime":"0","summary":"The marketing authorization is applicable to all 27 European Union member states as well as营销授权适用于所有27个欧盟成员国以及. The Sephience European launch will be initiated in. Sephience 的欧洲上市将在Germany德国in the first half of July.在七月份的上半月。By enhancing the conformational stability of misfolded PAH enzyme and increasing the intracellular concentrations of BH4, Sephience is able to effectively reduce blood Phe levels. Sephience is approved in the European Economic Area. Sepiapterin is an investigational new drug in .通过增强错误折叠的PAH酶的构象稳定性并增加细胞内BH4的浓度，Sephience能够有效降低血液中的Phe水平。Sephience已在欧洲经济区获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625095137978dafae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625095137978dafae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU2477742899.HKD","LU1923623000.USD","BK4576","LU0109394709.USD","LU1951200564.SGD","LENZ","BK4588","PTCT","BK4139","LU1721428347.USD","LU1951198990.SGD","LU2362541513.USD","LU2506952337.HKD","BK4023","BK4539","BK4007","LU2362541273.HKD","LU0320765992.SGD","LU2506952410.USD","BK4554","LU2362540622.SGD","PTC","LU0889565916.HKD"],"gpt_icon":0},{"id":"2517334467","title":"PTC Therapeutics(PTCT.US)获Scotiabank首次覆盖，给予与大盘持平评级, 目标价55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517334467","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517334467?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:42","pubTimestamp":1741387360,"startTime":"0","endTime":"0","summary":"PTC Therapeutics(PTCT.US)获Scotiabank首次覆盖，给予与大盘持平评级, 目标价55.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08064248605342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PTC","PTCT"],"gpt_icon":0},{"id":"2517529624","title":"Ptc Therapeutics, Inc.2024财年实现净利润-3.63亿美元，同比增加42.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517529624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517529624?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363251,"startTime":"0","endTime":"0","summary":"3月8日，Ptc Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-3.63亿美元，同比增加42.11%；其中营业收入为8.07亿美元，同比减少13.97%，每股基本收益为-4.73美元。从资产负债表来看，Ptc Therapeutics, Inc.总负债28.15亿美元，其中短期债务13.36百万美元，资产负债比为0.61，流动比率为2.36。机构评级：截至2025年3月8日，当前有15家机构对Ptc Therapeutics, Inc.目标价做出预测，其中目标均价为62.67美元，其中最低目标价为41.00美元，最高目标价为113.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000221a2647f70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000221a2647f70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTCT","LENZ"],"gpt_icon":0},{"id":"2516677198","title":"Ptc Therapeutics, Inc.盘中异动 股价大跌5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677198","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677198?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:36","pubTimestamp":1741098993,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时36分，Ptc Therapeutics, Inc.股票出现波动，股价大幅跳水5.52%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Exicure, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1082.56%、1072.80%、425.75%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Adma Biologics Inc，振幅分别为23.30%、22.25%、12.57%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223634abe7f167&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223634abe7f167&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LENZ","BK4139","PTCT","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2516727371","title":"小摩：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至72.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516727371","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516727371?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:45","pubTimestamp":1740761122,"startTime":"0","endTime":"0","summary":"小摩：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由74.00美元调整至72.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01004548469593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTCT","LENZ","PTC"],"gpt_icon":0},{"id":"1142137500","title":"PTC Therapeutics 2024年第四季度调整后每股收益$(0.85) 低于预期$(0.66)，销售额$2.13亿 低于预期$2.3244亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1142137500","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142137500?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:18","pubTimestamp":1740691133,"startTime":"0","endTime":"0","summary":"PTC Therapeutics报告季度每股亏损$，低于分析师一致预期的$，差距为28.79%。公司报告季度销售额为$2.13亿美元，低于分析师一致预期的$2.3244亿美元，差距为8.36%。与去年同期的$3.0706亿美元销售额相比，同比下降30.63%。以上内容来自Benzinga Earnings专栏，原文如下：PTC $Therapeutics$ reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 28.79 percent. This is a 254.17 percent decrease over losses of $ per share from the same period last year. The company reported quarterly sales of $213.00 million which missed the analyst consensus estimate of $232.44 millio","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTC","PTCT"],"gpt_icon":0},{"id":"2512198714","title":"加拿大皇家银行：维持PTC Therapeutics(PTCT.US)评级，由优于大市调整至优于大市评级, 目标价由60.00美元调整至63.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512198714","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512198714?lang=zh_cn&edition=full","pubTime":"2025-02-19 01:58","pubTimestamp":1739901520,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持PTC Therapeutics(PTCT.US)评级，由优于大市调整至优于大市评级, 目标价由60.00美元调整至63.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19015848243282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PTC","PTCT"],"gpt_icon":0},{"id":"2508999123","title":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由76.00美元调整至113.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508999123","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508999123?lang=zh_cn&edition=full","pubTime":"2025-02-04 00:54","pubTimestamp":1738601652,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由76.00美元调整至113.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/04005447942318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTC","PTCT","LENZ"],"gpt_icon":0},{"id":"2508371144","title":"Ptc Therapeutics, Inc.盘中异动 快速上涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508371144","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508371144?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:51","pubTimestamp":1738594261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时51分，Ptc Therapeutics, Inc.股票出现波动，股价快速拉升5.11%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为428.16%、363.02%、229.18%，振幅较大的相关个股有Hcw Biologics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Briacell Therapeutics Corp.，振幅分别为97.05%、50.76%、36.85%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225101abc10be7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225101abc10be7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTCT","BK4139","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2503464870","title":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由80.00美元调整至76.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503464870","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503464870?lang=zh_cn&edition=full","pubTime":"2025-01-15 20:53","pubTimestamp":1736945635,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：维持PTC Therapeutics(PTCT.US)评级，由增持调整至增持评级, 目标价由80.00美元调整至76.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15205347495124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PTCT","LENZ","PTC"],"gpt_icon":0},{"id":"2490019466","title":"Ptc Therapeutics, Inc.盘中异动 快速拉升6.08%报50.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490019466","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490019466?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:31","pubTimestamp":1733841077,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时31分，Ptc Therapeutics, Inc.股票出现波动，股价快速拉升6.08%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为1643.12%、399.04%、84.92%，振幅较大的相关个股有Newamsterdam Pharma Company N.V.、Lava Therapeutics N.V.、Silexion Therapeutics Corp，振幅分别为10.21%、9.95%、9.70%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223117ab6cf51e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223117ab6cf51e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","PTCT","BK4139","LENZ","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2488492247","title":"Ptc Therapeutics, Inc.盘中异动 下午盘股价大跌5.17%报49.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488492247","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488492247?lang=zh_cn&edition=full","pubTime":"2024-12-04 03:06","pubTimestamp":1733252760,"startTime":"0","endTime":"0","summary":"北京时间2024年12月04日03时06分，Ptc Therapeutics, Inc.股票出现异动，股价急速跳水5.17%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.80%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。消息层面，截至03时06分，《PTC Therapeutics与诺华制药签署亨廷顿病药物许可协议》资讯为影响Ptc Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204030600abf37014&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204030600abf37014&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","PTCT","BK4139"],"gpt_icon":0},{"id":"2488708526","title":"Ptc Therapeutics, Inc.股价飙升15.43% 市值涨6.03亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488708526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488708526?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:31","pubTimestamp":1733149882,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日22时31分，Ptc Therapeutics, Inc.股票出现波动，股价大幅上涨15.43%。Ptc Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Senti Biosciences, Inc.、Purple Biotech Ltd、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Purple Biotech Ltd、Senti Biosciences, Inc.、Revelation Biosciences, Inc.较为活跃，换手率分别为643.05%、635.36%、201.02%，振幅较大的相关个股有Senti Biosciences, Inc.、Renovaro Inc.、Precigen, Inc.，振幅分别为16.20%、6.61%、6.40%。Ptc Therapeutics, Inc.公司简介：PTC Therapeutics Inc 是一家生物制药公司，专注于口服小分子疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223122a2669857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202223122a2669857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LENZ","BK4139","PTCT","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2488067958","title":"PTC Therapeutics(PTCT.US)与诺华制药(NVS.US)签署亨廷顿病药物许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2488067958","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488067958?lang=zh_cn&edition=full","pubTime":"2024-12-02 21:23","pubTimestamp":1733145808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美国生物制药公司PTC Therapeutics的股价周一盘前上涨21%，此前该公司与诺华制药签署了PTC518亨廷顿病项目的独家全球许可和合作协议。PTC518目前正在进行2期PIVOT-HD试验，并显示出良好的安全性和耐受性。该协议预计将于2025年第一季度完成。根据协议，PTC Therapeutics 将获得10亿美元的预付款，高达19亿美元的开发、监管和销售里程碑，在美国的利润分成为40%，并在美国以外的地区获得两位数的销售分层版税。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2506952337.HKD","LU0320765992.SGD","IE00B2B36J28.USD","IE0002141913.USD","BK4532","LU1951198990.SGD","LU2362540622.SGD","BK4585","BK4578","BK4139","LU1951200564.SGD","BK4023","IE00BJT1NW94.SGD","LU2362541513.USD","PTCT","BK1191","LU1721428347.USD","IE00B4R5TH58.HKD","LU2362541273.HKD","LENZ","IE00BFTCPJ56.SGD","BK1574","NVS","LU2477742899.HKD","LU0211331839.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","BK4007","BK4554","LU0109394709.USD","PTC","BK4576","LU2506952410.USD","IE0009355771.USD","01477","BK4588","LU1923623000.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ptcbio.com","stockEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.0274},{"period":"3month","weight":0.2333},{"period":"6month","weight":0.4859},{"period":"1year","weight":0.6408},{"period":"ytd","weight":0.6524}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ptc Therapeutics, Inc.于1998年3月31日注册成立为一家特拉华州公司。 PTC Therapeutics股份有限公司是一家生物制药公司，专注于用于转录后控制过程中的口服药，专有的小分子药物的发现和开发。同时该公司的研发计划针对于多个治疗领域，公司特别专注于孤儿和超孤儿混乱疾病的治疗的开发和商业化。公司主导的候选产品是ataluren，该产品用于治疗过程中所出现的一种被称为无义突变基因突变的遗传性疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.100896},{"month":2,"riseRate":0.583333,"avgChangeRate":0.010715},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.07295},{"month":4,"riseRate":0.5,"avgChangeRate":0.024923},{"month":5,"riseRate":0.5,"avgChangeRate":0.022752},{"month":6,"riseRate":0.583333,"avgChangeRate":0.052418},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026829},{"month":8,"riseRate":0.692308,"avgChangeRate":0.062649},{"month":9,"riseRate":0.538462,"avgChangeRate":0.038954},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.075074},{"month":11,"riseRate":0.692308,"avgChangeRate":0.134491},{"month":12,"riseRate":0.615385,"avgChangeRate":0.030238}],"exchange":"NASDAQ","name":"PTC Therapeutics Inc.","nameEN":"PTC Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PTC Therapeutics Inc.,PTCT,PTC Therapeutics Inc.股票,PTC Therapeutics Inc.股票老虎,PTC Therapeutics Inc.股票老虎国际,PTC Therapeutics Inc.行情,PTC Therapeutics Inc.股票行情,PTC Therapeutics Inc.股价,PTC Therapeutics Inc.股市,PTC Therapeutics Inc.股票价格,PTC Therapeutics Inc.股票交易,PTC Therapeutics Inc.股票购买,PTC Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PTC Therapeutics Inc.(PTCT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PTC Therapeutics Inc.(PTCT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}